Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial

Alberto Palazzuoli1*, Marco Pellegrini1, Gaetano Ruocco1, Giuseppe Martini1, Beatrice Franci1, Maria Stella Campagna1, Marilyn Gilleman1, Ranuccio Nuti1, Peter A McCullough2 and Claudio Ronco3

Abstract

Introduction: Intravenous loop diuretics are a cornerstone of therapy in acutely decompensated heart failure (ADHF). We sought to determine if there are any differences in clinical outcomes between intravenous bolus and continuous infusion of loop diuretics.

Methods: Subjects with ADHF within 12 hours of hospital admission were randomly assigned to continuous infusion or twice daily bolus therapy with furosemide. There were three co-primary endpoints assessed from admission to discharge: the mean paired changes in serum creatinine, estimated glomerular filtration rate (eGFR), and reduction in B-type natriuretic peptide (BNP). Secondary endpoints included the rate of acute kidney injury (AKI), change in body weight and six months follow-up evaluation after discharge.

Results: A total of 43 received a continuous infusion and 39 were assigned to bolus treatment. At discharge, the mean change in serum creatinine was higher (+0.8 ± 0.4 versus -0.8 ± 0.3 mg/dl \( P < 0.01 \)), and eGFR was lower (-9 ± 7 versus +5 ± 6 ml/min/1.73 m\(^2\) \( P < 0.05 \)) in the continuous arm. There was no significant difference in the degree of weight loss (-4.1 ± 1.9 versus -3.5 ± 2.4 kg \( P = 0.23 \)). The continuous infusion arm had a greater reduction in BNP over the hospital course, (-576 ± 655 versus -181 ± 527 pg/ml \( P = 0.02 \)). The rates of AKI were comparable (22% and 15% \( P = 0.3 \)) between the two groups. There was more frequent use of hypertonic saline solutions for hyponatremia (33% versus 18% \( P < 0.01 \)), intravenous dopamine infusions (35% versus 23% \( P = 0.02 \)), and the hospital length of stay was longer in the continuous infusion group (14.3 ± 5 versus 11.5 ± 4 days, \( P < 0.03 \)). At 6 months there were higher rates of re-admission or death in the continuous infusion group, 58% versus 23%, \( (P = 0.001) \) and this mode of treatment independently associated with this outcome after adjusting for baseline and intermediate variables (adjusted hazard ratio = 2.57, 95% confidence interval, 1.01 to 6.58 \( P = 0.04 \)).

Conclusions: In the setting of ADHF, continuous infusion of loop diuretics resulted in greater reductions in BNP from admission to discharge. However, this appeared to occur at the consequence of worsened renal filtration function, use of additional treatment, and higher rates of rehospitalization or death at six months.

Trial registration: ClinicalTrials.gov NCT01441245. Registered 23 September 2011.
Introduction
The use of intravenous loop diuretics is a cornerstone of therapy for acutely decompensated heart failure (ADHF) treatment, especially in patients admitted with pulmonary congestion and volume overload. Significant concerns have been raised regarding the risks and benefits of loop diuretics, especially about the dosage and administration regimen [1,2]. Recent guidelines recommend the use of loop diuretics to reduce left ventricular filling pressure, avoid pulmonary edema, and alleviate peripheral fluid retention [3]. Therapeutic recommendations focus primarily on symptom relief because there are no specific strategies showing a clear benefit in the outcome of ADHF. Despite the ubiquity of loop diuretic administration, high quality data supporting their efficacy and best modulation of administration are lacking. In addition, impaired renal function has consistently been proven to be an independent risk factor for adverse outcomes and a leading reason why higher doses and continuous infusions are used. The use of high doses of loop diuretics has been associated with unfavorable neuroendocrine activation, worsening renal function, electrolyte disturbances, and a poor outcome [4,5]. Although loop diuretics are the most commonly used drugs in ADHF treatment, their short- and long-term effects are relatively unknown; thus, it is recommended to administer the lowest dosage to patients with ADHF in order to relieve their symptoms [5]. Some studies have provided guidelines for the administration of these drugs in clinical practice, but data interpretation remains challenging due to the frequent exclusion of patients with kidney disease from major ADHF clinical trials. Therefore, it is not clear if continuous infusion is better than intermittent boluses in terms of decongestion, maintenance of renal filtration function, and prognosis [6,7]. In theory, intermittent boluses could lead to more unfavorable hemodynamic changes, be associated with a higher rate of diuretic resistance due to suboptimal drug levels in the renal tubules, and result in a rebound in sodium reabsorption. On the other hand, continuous administration should provide more constant delivery of diuretic into the tubule, potentially reducing this phenomenon. Additionally, continuous infusion may induce an increased diuresis, reducing systemic and pulmonary congestion more efficaciously, thus avoiding sudden blood pressure reduction induced by bolus administration. However, for the same reasons, continuous infusion is associated with sustained neuroendocrine activation and electrolyte imbalance that could potentially be reduced by intermittent administration.

The Diuretic Optimization Strategies Evaluation (DOSE) trial was a prospective, double-blind study in which researchers randomly assigned 308 subjects with ADHF to high-dose and low-dose and continuous versus intermittent infusion of furosemide. This study did not reveal positive outcomes in either primary or secondary endpoints comparing continuous infusion to a bolus regimen. However, there were higher rates of acute kidney injury (AKI) in the high-dose arm [8]. Thus, equipoise remains on this issue. Our study aimed to evaluate the effects of continuous infusion of furosemide in comparison with a twice daily regimen at similar doses, on biomarker and clinical parameters.

Methods
Study design
This was a prospective, randomized, open label, double-blind study comparing continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF into our tertiary-care medical center. The current pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate most optimal loop diuretic strategies in patients with ADHF.

Patients were enrolled consecutively from the Department of Internal Medicine, Cardiology Section Center (Siena, Italy) from April 2010 to November 2012. All patients enrolled were submitted to continuous electrocardiography and blood pressure monitoring as well as regular measurements of urine output. We hypothesized that continuous infusion treatment could be superior to bolus intermittent administration to relieve congestion, increase diuresis and decrease B-type natriuretic peptide (BNP) levels.

Patients were eligible if they were admitted with a primary diagnosis of ADHF, could be randomized within 12 h after hospital presentation and had evidence of volume overload (pulmonary congestion on chest radiography or significant increase in BNP levels). Some patients received noninvasive ventilation support before randomization (10 in the continuous and 7 in the bolus group). The cumulative daily dose of intravenous furosemide to be given in the initial 12 h was decided upon by the attending physician. Patients were then randomized in a 1:1 ratio using a computer-generated scheme into either twice-daily bolus injections or continuous infusion (mixed as a 1:1 ratio in 5% dextrose in water), for a time period ranging from 72 to 120 h. Boluses of furosemide were administered in 100 ml of water solution in one hour. The mean daily diuretic dosage was similar in both groups as a result of the protocol (Figure 1).

Before randomization, renal function parameters and BNP levels were measured in all patients. Therefore, all patients were submitted to echocardiography and chest radiography to assess pulmonary congestion. Chest radiography was also repeated promptly before treatment disruption to verify pulmonary congestion improvement. Subsequent titration of the furosemide dosage was guided by a dose-escalation algorithm based on the patient’s response to the treatment (body weight (BW) loss <1 kg from the starting enrollment to the third day or urine
output <1,000 mL/day), signs of recovery (decreased pulmonary rales, venous jugular congestion, additive heart sounds, improvement in pulmonary congestion on chest radiography), and/or by important changes in renal function, such as a sudden increase of creatinine >0.8 mg/dl compared to the baseline value or hypokalemia below 3.2 mEq/L. The specific doses of furosemide and the use of additional agents to manage ADHF (dopamine, intravenous (IV) vasodilators, hypertonic saline infusions for hyponatremia) were decided upon based on the above cited laboratory and clinical parameters, with daily dosages adjusted during the infusion periods. Specifically in the case of poor initial diuretic response, the furosemide dosage was doubled. In case of diuretic resistance, defined as diuresis below 1,000 mL/day, the dosage was escalated up to 250 mg/day.

Supplementary treatment was left to the discretion of the treating physician. All patients took angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and nitrates. No thiazide diuretics, nesiritide, or arginine vasopressin antagonists were administered during the hospitalization period. Hypertonic saline solution was administered to the patients who developed hyponatremia (serum Na values <128 mEq/L) during treatment with the goal of restoring plasma sodium values up to 134 mEq/L. For this reason Na concentration was monitored each day during the infusion period. The hypertonic saline solution consisted of 20 mEq of NaCl in 500 mL saline solutions (0.9% of NaCl). Infusion was administered at 80 cc/h once or twice a day, depending on the Na value [9]. Dopamine infusions were administered to patients with systolic blood pressure <90 mmHg with the goal of restoring systolic values up to 100 mmHg maintaining diuretic infusion. Inotrope therapy was stopped when blood pressure values were sustained at approximately 105 mmHg during 12 sequential hours for four consecutive measurements.

The frequency of laboratory tests to evaluate electrolyte balance and renal function during hospitalization was at the discretion of the attending physician but was guided by a dose-escalation algorithm. This trial was approved by our hospital’s Institutional Review Board of Siena and all patients gave their signed informed consent. This trial was registered and regularly updated in ClinicalTrials.gov with Identifier number: NCT01441245.

**Inclusion criteria**

Patients over age 18 years of age were screened if they met diagnostic criteria for ADHF due to systolic dysfunction and left ventricular ejection fraction (LVEF) <45% by exhibiting at least one of the following symptoms at rest: dyspnea, orthopnea, peripheral edema or major fatigue and at least two clinical signs including rales, pulmonary congestion on chest radiography, jugular vein dilatation,
or a third heart sound. Elevations in blood BNP >400 pg/mL were considered supportive for a diagnosis of ADHF.

**Exclusion criteria**

Patients were excluded if they had received more than two IV doses of furosemide or any continuous infusion of furosemide one month before randomization, if they had end-stage renal disease or the need for renal replacement therapy (dialysis or ultrafiltration), isolated diastolic dysfunction with LVEF >45% or recent myocardial infarction within thirty days of screening. Patients with a systolic blood pressure <80 mm Hg or with serum creatinine levels >4.0 mg/dL were also excluded, as well as patients who received recent intravenous iodinated contrast.

**Laboratory analysis**

Complete blood analysis with hemoglobin concentration, hematocrit, red blood cell count, serum creatinine, sodium, and potassium were performed at the time of admission to determine the baseline criteria, and subsequent testing was performed each day and again at the time of discharge. The estimated glomerular filtration rate (eGFR) was calculated using the four-variable formula, modification of diet in renal disease (MDRD). Mild kidney dysfunction was defined by eGFR less than 60 mL/min/1.73 m², and moderate kidney dysfunction as eGFR 15 to 29 mL/min/1.73 m² based on chronic kidney disease (CKD) stages. A rise in serum creatinine ≥0.3 mg/dl or urine output <0.5 mL/kg/h × 6 h was used according to conventional criteria to define AKI [10]. This measurement was calculated from admission to the end of diuretic infusion treatment. Plasma BNP was measured at baseline and at the end of infusion period using an immunofluorescence assay manufactured by Inverness (San Diego, CA, USA). The analytic sensitivity of the assay is <5 pg/mL and the upper limit of normal is considered to be <100 pg/mL.

**In-hospital outcomes**

The co-primary endpoints at discharge were the mean paired changes in creatinine, eGFR, body weight (BW), and BNP. Additional in-hospital outcomes assessed included the rate of AKI, the use of hypertonic saline and inotropic agents, and length of hospital stay.

**Late outcomes**

Death and rehospitalization because of worsening heart failure were captured up to 6 months after discharge. If the hospitalization was for heart-failure-related events such as pump failure, acute coronary syndromes complicated by heart failure, ventricular arrhythmias associated with left ventricular dysfunction, or heart failure associated with worsened renal function, for analytical purposes these were all considered as hospitalization for heart failure.

**Sample size estimation**

The sample size used was preliminarily calculated on the basis of three co-primary endpoints including the following assumptions: 1) a 30% or greater effect size in the difference between mean paired changes in continuous co-primary endpoints (eGFR, creatinine, and BNP); SD data from each group no greater than 20%; 2) alpha = 0.05 two-tailed, 3) power (1-beta) = 80%. Thus, the calculated sample size was 52 subjects (26 in each group) and we assumed no patients would withdraw or be lost during the hospitalization. We also anticipated that 20% of subjects could be lost to follow up after hospital discharge.

**Statistical analysis**

All data were analyzed with intention-to-treat principles. Continuous variables were expressed as mean ± SD and compared using the Student t-test (unpaired and paired as appropriate) for independent groups if normally distributed; normality was assessed by the Kolmogorov-Smirnov test. Analysis of variance was done by Levene’s test, and if it was breached Welch’s correction was used. Cox regression analysis was used to assess the independent relationship between the two methods of furosemide infusion for the outcome of rehospitalization or death, with adjustment for age, gender, creatinine, eGFR, and BNP at baseline, the use of hyperosmolar solution, dopamine infusion, and the development of AKI. Kaplan-Meier methods were employed to generate survival plots that were compared using a log-rank test for time to first hospitalization, death, or the composite. All statistical tests were two-tailed, with a P-value <0.05 considered significant. All the analyses were performed by using the SPSS 20.0 for Windows (SPSS Inc, Chicago, IL, USA).

**Results**

**Baseline characteristics**

A total of 128 patients were consecutively admitted and screened with diagnosis of ADHF; of these patients 22 were excluded for preserved ejection fraction, 8 for recent myocardial infarction, 8 for incomplete laboratory assessments at baseline, and 6 for severe renal disease. Of the 84 patients 2 were subsequently excluded because of missing data (weight, and BNP). Thus, 82 patients met the inclusion criteria and were randomly assigned to one of the two groups: continuous infusion, n = 43 or bolus therapy, n = 39 (Figure 1). The median time from presentation to randomization was 9 ± 3 h, and the median duration of study-drug administration was 112 ± 24 h. Table 1 provides patient’ characteristics in each
group at the time of enrollment. The overall age was 72 ± 8 years, LVEF 35 ± 10%, serum creatinine 1.6 ± 0.5 mg/dl, and plasma BNP level 1156 ± 640 pg/Ml, with no significant differences between the randomized arms. The mean cumulative daily doses of furosemide chosen by the attending physicians were similar in both arms (continuous infusion: 170 ± 70 mg/day, bolus therapy 160 ± 80 mg/day).

Laboratory values and urine output
At the end of treatment period, continuous infusions resulted in greater urine output (2295 ± 755 versus 2090 ± 421 mL, \( P < 0.002 \)); higher achieved serum creatinine values (1.78 ± 0.6 versus 1.34 ± 0.3 mg/dl \( P < 0.0001 \)), lower eGFR (40.6 ± 10.5 versus 50.4 ± 11.4 mL/min/1.73 m², \( P < 0.01 \)), and higher blood urea nitrogen levels (100 ± 60 vs 69 ± 31 mg/dl, \( P < 0.02 \)). After the randomized treatment period of approximately 120 hours, the mean plasma BNP was lower in the continuous infusion arm (723 ± 497 versus 822 ± 548 pg/Ml, \( P = 0.05 \)). By hospital discharge, there were lower potassium levels in the continuous arm (3.6 ± 0.8 versus 4.0 ± 0.7 mEq/L, \( P < 0.04 \)), reductions from baseline (-0.5 ± 1.4 versus -0.3 ± 0.9 mEq/L), however there were no significant differences in serum sodium (+1 ± 6 versus -3 ± 7 mEq/L) (Table 2).

Primary endpoints
The mean change in serum creatinine was higher (+0.8 ± 0.4 versus -0.8 ± 0.3 mg/dl, \( P < 0.01 \)), and eGFR lower (-9 ± 7 versus +5 ± 6 mL/min/1.73 m², \( P < 0.05 \)) in the continuous infusion arm. However, the mean reduction in BNP concentration from baseline to discharge was significantly greater with the continuous infusion compared to the bolus infusion (-576 ± 655 versus -181 ± 527 pg/mL, \( P = 0.02 \)) (Table 3).

As for the secondary outcomes, the incidence of AKI was similar (continuous arm 10 patients (22%) and bolus arm 6 patients (15%) \( P = 0.3 \)) for the two groups. There was more frequent use of hypertonic saline solutions for hypernatremia (33% versus 18%, \( P < 0.01 \)), intravenous dopamine infusions (35% versus 23%, \( P = 0.02 \)), and the hospital length of stay was longer in the continuous infusion group (14.3 ± 4 versus 11.5 ± 4 days, \( P < 0.03 \)) (Table 4). There was no significant difference in the degree of weight loss -4.1 ± 1.9 versus -3.5 ± 2.4 kg, \( P = 0.23 \). A total of 26 patients died (31%) and 35 (41%) had a new hospitalization during follow up. At 6 months there were higher rates of re-admission or death in the continuous infusion group, with 58% versus 23%, \( P = 0.001 \) (Figure 2).

Multivariate results and late outcome
Univariate analysis for the composite outcome of rehospitalization or death at 6 months found that blood urea

Table 1: Baseline characteristics of the study population

| Characteristic                              | Continuous infusion (n = 43) | Bolus (n = 39) |
|--------------------------------------------|-----------------------------|---------------|
| Age (years)                                | 80 ± 4                      | 79 ± 5        |
| Sex                                         |                             |               |
| Female                                      | 24                          | 18            |
| Male                                        | 19                          | 21            |
| Baseline weight (kg)                        | 72 ± 7                      | 69.7 ± 10     |
| Blood pressure (mmHg)                       | 142/87                      | 145/86        |
| Heart rate (beats/minute)                   | 102 ± 12                    | 98 ± 16       |
| Cardiac disease                             |                             |               |
| Coronary artery disease                     | 24                          | 21            |
| Idiopathic cardiomyopathy                  | 7                           | 7             |
| Hypertrophic cardiomyopathy                | 4                           | 6             |
| Valvular disease                            | 8                           | 5             |
| Baseline creatinine (mg/dl)                 | 1.62 ± 0.5                  | 1.52 ± 0.4    |
| BUN                                         | 100.60 ± 60                 | 69.2 ± 31     |
| eGFR (mL/min/1.73 m²)                       | 43.2 ± 7.6                  | 45.7 ± 8.7    |
| Serum sodium (mEq/L)                       | 137.2 ± 5                   | 138 ± 5       |
| Serum potassium (mEq/L)                    | 4.19 ± 0.4                  | 4.26 ± 0.5    |
| Left ventricular ejection fraction (%)      | 34.3 ± 10                   | 35.8 ± 8      |
| LV internal diastolic diameter (mm)         | 68 ± 8                      | 66 ± 9        |
| LV internal systolic diameter (mm)          | 48 ± 10                     | 45 ± 8        |
| Estimated Pulmonary Artery (PA) systolic pressure (mmHg) | 50 ± 6                      | 48 ± 5        |
| Signs of congestion                        |                             |               |
| Elevated jugular venous pressure            | 16                          | 18            |
| Additive heart sound                        | 11                          | 13            |
| Peripheral edema                            | 33                          | 30            |
| Pulmonary rales                             | 38                          | 35            |
| Coronary risk factors (%)                  |                             |               |
| Diabetes mellitus                           | 55.2                        | 61.1          |
| Hypertension                                | 89.4                        | 87.9          |
| Dyslipidemia                                | 72.4                        | 75            |
| Previous Coronary artery disease (CAD)      | 46.2                        | 49.4          |
| Atrial fibrillation (%)                     | 36.6                        | 41.3          |
| Baseline BNP (pg/mL)                        | 1204 ± 693                  | 1099 ± 571    |
| Previous therapy                            |                             |               |
| ACE-inhibitors                              | 38                          | 33            |
| β-Blockers                                  | 22                          | 21            |
| Nitrates                                    | 25                          | 26            |
| Diuretics                                   | 39                          | 35            |
| Angiotensin receptor blockers               | 5                           | 7             |
| Digoxin                                     | 13                          | 11            |
| Aldosterone antagonist                      | 15                          | 12            |

Results are presented as mean ± SD or number, unless stated otherwise. BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; LV, Left Ventricular; BNP, B-type natriuretic peptide.
nitrogen (BUN) and randomization to continuous loop diuretics were the only baseline variables that were significantly associated with poor outcome. Additionally, serum creatinine, eGFR, and plasma BNP after the randomized treatment period (approximately 120 h) were associated with rehospitalization or death as shown in Table 5. When these variables were tested in a Cox proportional hazards model which included age, gender, baseline creatinine, eGFR, BUN and BNP, use of hyperosmolar solutions, dopamine infusions, eGFR after the treatment period, and the development of AKI, only randomization to continuous infusion (hazard ratio (HR) = 2.57, 95% CI 1.01, 6.58, P = 0.04), and after the treatment period (approximately 120 h) the serum creatinine above 1.5 mg/dl (HR = 6.40, 95% CI 1.25, 32.62, P = 0.02), and BNP above 500 pg/mL (HR = 1.01, 95% CI 1.00, 1.02, P = 0.04), remained significantly associated with rehospitalization or death. The Kaplan-Meier curve showed that in continuous arm there was an increased events rate during the 180-day observational period after discharge (Figure 3).

Discussion
Loop diuretic therapy is considered the cornerstone for heart failure (HF) management, particularly during episodes of acute decompensation. More than 90% of patients admitted for HF are treated with this drug [2,3]. Although mentioned in guidelines for ADHF, there is little evidence to support a preferred dose, route of administration, or method of intravenous infusion [6,11]. Furthermore, observational studies have demonstrated that higher cumulative doses of loop diuretics have been associated with worsened outcomes [12,13]. Thus, our trial had an excellent setting to allow clinicians to choose a cumulative daily dose of diuretics and then randomize patients to a continuous versus bolus administration of loop diuretics.

Continuous versus intermittent loop diuretic administration
We found a few clinical advantages to the use of continuously infused loop diuretics in that there appeared to be a greater urine output after 24 h and a greater reduction in BUN after approximately 5 days. All other clinical factors favored the use of intermittent twice daily bolus administration including the change in serum creatinine, eGFR, need for the use of hypertonic saline for hyponatremia, use of inotropic agents, length of hospital stay, and rehospitalization or death at 6 months.

Importantly, after we adjusted for intermediate outcomes and physician responses to clinical changes, we found that randomization to continuous infusion therapy was strongly associated with rehospitalization and death at 6 months. The power of this evaluation is low due to low numbers of subjects. Thus, despite any theoretical advantages of continuous administration, we found no clinical benefit; in fact there was evidence of harm with this approach. All of these effects related either to greater diuresis or preexisting undocumented morbidity would be expected to worsen outcomes. Our findings revealed a bimodal effect of continuous infusion: despite a significant decrease in BNP levels we found an increase in eGFR and creatinine, such a trend seems to reflect the late outcome. The current course should evidence the prognostic impact of AKI compared to BNP reduction during hospitalization could have more unfavorable impact in our population. Findings of multivariate analysis appear in line with the current observation: both BNP and creatinine at discharge revealed a prognostic impact; although creatinine together with type of treatment, provide evidence of a more significant value. Moreover, patients in the continuous infusion arm were more

---

Table 2 Comparison of biochemical measures and urine output after the randomized treatment period of approximately 120 h

|                      | Continuous infusion | Bolus     | P-value |
|----------------------|---------------------|-----------|---------|
| Urine output/24 h (mL) | 2295 ± 775          | 2090 ± 421| <0.002  |
| Serum creatinine (mg/dl) | 1.78 ± 0.6          | 1.34 ± 0.3| <0.0001 |
| eGFR (mL/min/1.73 m²) | 40.6 ± 10.5         | 50.4 ± 11.4| <0.01   |
| BUN (mg/dl)          | 100 ± 60            | 69 ± 31   | <0.02   |
| BNP (pg/mL)          | 723 ± 497           | 822 ± 548 | <0.05   |
| Serum sodium (mEq/L) | 138 ± 4             | 135 ± 16  | NS      |
| Serum potassium (mEq/L) | 3.6 ± 0.8           | 4.0 ± 0.7 | <0.04   |

Results are presented as mean ± SD. eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; BNP, B-type natriuretic peptide. NS, not significant.

Table 3 Co-primary endpoints expressed as change from baseline to discharge in values

|                      | Continuous infusion | Bolus     | P-value |
|----------------------|---------------------|-----------|---------|
| Δ Serum creatinine (mg/dl) | +0.8 ± 0.4         | -0.8 ± 0.3| <0.01   |
| Δ eGFR (mL/min/1.73 m²) | -9 ± 7              | +5 ± 6    | <0.05   |
| Δ BNP (pg/mL)        | -576 ± 655          | -181 ± 527| 0.02    |

Results are presented as mean ± SD. Δ = mean change from admission to discharge. Difference; eGFR, estimated glomerular filtration rate; BNP, B-type natriuretic peptide.

---

Table 4 Secondary endpoints in the continuous infusion versus bolus arm

|                      | Continuous infusion | Bolus     | P-value |
|----------------------|---------------------|-----------|---------|
| Acute kidney injury  | 22%                 | 15%       | 0.30    |
| Hypertonic saline solution | 33%             | 18%       | 0.01    |
| Inotropes infusion   | 35%                 | 23%       | 0.02    |
| Length of hospital stay (days), mean ± SD | 14 ± 5              | 11 ± 5    | <0.03   |
| Death or rehospitalization | 58%              | 23%       | 0.001   |
| Weight loss (kg), mean ± SD | -4.1 ± 1,9        | -3.5 ± 2.4| 0.23    |

Continuous administration was strongly associated with rehospitalization and death at 6 months. The power of this evaluation is low due to low numbers of patients. Thus, despite any theoretical advantages of continuous administration, we found no clinical benefit; in fact there was evidence of harm with this approach. All of these effects related either to greater diuresis or preexisting undocumented morbidity would be expected to worsen outcomes. Our findings revealed a bimodal effect of continuous infusion: despite a significant decrease in BNP levels we found an increase in eGFR and creatinine, such a trend seems to reflect the late outcome. The current course should evidence the prognostic impact of AKI compared to BNP reduction during hospitalization could have more unfavorable impact in our population. Findings of multivariate analysis appear in line with the current observation: both BNP and creatinine at discharge revealed a prognostic impact; although creatinine together with type of treatment, provide evidence of a more significant value. Moreover, patients in the continuous infusion arm were more
often submitted to dobutamine therapy, and this could have biased the outcome findings.

**Pharmacology of loop diuretics**

In patients with ADHF treated with loop diuretics, compensatory pathophysiologic mechanisms to maintain vascular resistance, such as nonosmotic stimulation of vasopressin secretion and activation of the renin-angiotensin system, have been observed. Because intravenous loop diuretics, as observed in our study, result in an initial high-volume diuresis, the plasma refill of fluid from the extravascular space may be exceeded by early volume depletion, and thus create a risk for AKI [14]. Additionally, loop diuretics may directly impair renal function by reducing renal blood flow resulting in redistribution within the kidney and inducing a reduction in the effective filtration fraction [7,15]. More recent analyses, however, suggest that aggressive use of diuretics may be necessary in severe cases and that adverse effects may result from disease severity [16,17]. Thus, we recognize that in ADHF, higher doses of intravenous loop diuretics may be unavoidable, therefore, the remaining issue is how best to administer the therapy. In theory, continuous administration could be associated with higher drug concentrations at the loop of Henle, reducing energy requirements of the cells at the medullary level and consequently providing protection during hypoxic states. All these mechanisms lead to a resting state and a decrease in tubuloglomerular feedback. Therefore, a continuous modality should provide more constant urine output, less variation of intravascular volume, and less sodium reabsorption. These beneficial effects must be weighed against more sustained neuroendocrine activation, greater counter-regulatory attempts to increase sodium and water reabsorption, and efferent arteriole vasoconstriction for a prolonged period of time [15,17]. A recent Cochrane analysis was consistent with this rationale by demonstrating that continuous infusions ultimately resulted in lower urine outputs and greater rates of adverse events; unfortunately, no data were reported on long-term mortality or post-discharge events [18].

**Reduction in renal filtration, B-type natriuretic peptide, and outcomes**

We found that larger volumes of diuresis were associated with greater elevations in serum creatinine suggesting that the rate of salt and water loss exceeded that of plasma refill from the extra vascular compartment. A very similar observation was made in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial [19]. We found that despite greater reductions in BNP, there was worsened renal filtration function and no change in body weight. Studies have demonstrated that reductions in BNP are in general associated with improved short- and longer-term clinical outcomes, particularly when the reduction is more than 30% respect to admission level [20-22]. We found the differential reduction in BNP between the two groups was modest.

**Figure 2** Percentage of rehospitalization and death in all population (a); comparison of adverse events between continuous and bolus groups during 6-months follow-up period (b).

**Table 5 Univariate and multivariate hazard ratios (HR) for rehospitalization or death at six months**

| Variable          | Univariate              | Multivariate             |
|-------------------|-------------------------|--------------------------|
|                   | HR (95% CI of HR)       | P-value                  | HR (95% CI of HR)       | P-value                  |
| BUN               | 1.01 (1.00, 1.02)        | 0.03                     | 1.00 (0.99, 1.01)        | NS                      |
| BNP AT*           | 1.01 (1.00, 1.02)        | 0.03                     | 1.01 (1.00, 1.02)        | 0.04                    |
| eGFR AT*          | 0.98 (0.94, 1.03)        | NS                      | 1.06 (0.97, 1.15)        | NS                      |
| Creatinine AT*    | 2.43 (0.94, 6.35)        | NS                      | 6.40 (1.25, 32.62)       | 0.02                    |
| Continuous vs bolus| 2.91 (1.28, 6.63)        | 0.01                     | 2.57 (1.01, 6.58)        | 0.04                    |

*After treatment. *Multivariate analysis adjusted for age, gender, baseline creatinine, eGFR BUN and BNP, use of hyperosmolar solutions, dopamine infusions, eGFR AT, the development of acute kidney injury, eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen; BNP, B-type natriuretic peptide; NS, not significant.
and there was a wide range of BNP levels both before and after treatment. We observed a bimodal laboratory trend in the two arms: the continuous arm showed greater diuresis with better BNP reduction, Intermittent administration revealed less worsening renal function and less need for additive therapy. Thus, BNP is a single clinical parameter co-dependent on many variables related to left ventricular wall tension, degree of neurohormonal activation, and renal filtration function [23-25]. While many studies have focused on baseline values at the time of admission, we found that serum creatinine and BNP after the first 5 days of hospitalization was more significantly associated with 6-month outcomes [26-28]. Thus, our data suggest that in a clinical trial setting, the reduction in BNP does not appear to be a surrogate for improved renal or clinical outcomes in patients with ADHF, whereas basing of our finding, worsening renal function during hospitalization as well as basal renal dysfunction are two parameters that deserve better attention in clinical practice.

**Previous management studies**

The DOSE trial provided important information in determining the best method of administration of diuretics in this setting. Our results are partly in accordance with the DOSE trial which did not find superiority in either the dose (high versus low) or administration (infusion versus bolus) arms of a two-by-two factorial study [8]. Like DOSE, our trial found that continuous infusions at higher doses tended to result in a greater incidence of AKI. Our trial differed from DOSE in that our patients had greater degrees of baseline renal impairment, the loop diuretics were given for longer durations under the study protocol, and importantly, we found that the continuous infusion was associated with the need for more in-hospital therapies (inotropic infusions for hypotension and hypertonic saline for hyponatremia). This probably justifies a longer in-hospital stay together with worst basal conditions and older age; in respect to the DOSE trial patients moreover, most of them had comorbidities (as renal insufficiency anemic status and pulmonary disease). In addition, we found higher rates of rehospitalization and death in the continuous infusion arm. We did not evaluate symptom relief as in the DOSE trial, thus, there may have been a short-term differential strategy that we missed with our design. We preferred to use laboratory parameters and the endpoint of urine output because the symptom-stair is often misleading and does not perfectly reflect the congestion status and effective clinical improvement. Therefore the endpoints considered were demonstrated to have an effective impact on early outcome. Finally they may permit better tailoring of the dosing regimen for each patient during protocol escalation, avoiding the side effects of therapy. Other smaller studies comparing either dose or administration therapy have not yielded important conclusions beyond what can be reached from our trial or the DOSE trial, thus, additional research on optimal, inpatient treatment strategies is warranted in ADHF as well as in acute cardiorenal syndrome [18,29-32].

**Limitations**

Our trial has all the limitations of small, single-center randomized, pilot trials; however, except for the DOSE HF trial it is the largest study comparing the modality of loop diuretic administration in the acute HF setting. As a practical consideration in management, we had the attending physicians choose the cumulative daily dose of loop diuretic based on their judgment, and the randomization dictated the method of infusion, thus, treatment bias on dose as well as dose adjustments was not completely
handled in the protocol. Furthermore, we did not use a double-dummy design to blind the method of infusion. We did not have statistical power to evaluate differences in clinical outcomes during the hospitalization or at 6 months follow up. The multivariate analysis, including several risk factors and comorbidities, should be interpreted with caution because of the relatively small sample size. As in most randomized trials of ADHF, we did not change the background therapy in the protocol, thus, there was inherent non-uniform standard therapy (that is, nitrate, ACE-inhibitors, beta-blockers). As one of the outcomes, renal filtration function was calculated by the MDRD formula, which could have been influenced by several variables; the gold-standard calculation would be the direct measurement of creatinine clearance, which was not done in our study. Our findings arise from a pilot study that needs to be confirmed in large sample size, and for this reason we are pursuing the enrollment, and we intend to enlarge our protocol for a multicenter trial. We did not measure novel biomarkers, assess urinary sodium, or perform other assays that would have helped us in understanding why continuous infusions led to greater reductions in eGFR and worsened outcomes. Finally, our findings cannot be extended to patients with newly diagnosed HF or to those with lower diuretic requirements or perhaps better baseline renal function, where the response to diuretic strategies may be different.

Conclusions
Continuous infusions of loop diuretics in patients with ADHF appear to provide more efficient diuresis, together with better reduction of BNP levels in comparison with bolus therapy during the in-hospital period. However, this approach is associated with greater reductions in eGFR, needing of additional therapy for hypotension and hyponatremia, and longer hospitalization. These events appear to translate into higher rates of relhospitalization and death at 180 days. A larger multicenter study utilizing a more sophisticated assessment of volume overload and congestion, measurement of plasma refill from the extravascular compartment, and novel markers of both renal function and damage is needed to further understand how loop diuretics affect impact patients with ADHF and their short- and longer-term clinical outcomes. It is possible that degrees of physiologic tailoring of diuretic dose and administration are the next testable hypotheses in randomized trials that aim to improve outcomes in this population.

Key messages

- Continuous infusion of loop diuretics is associated with greater urine output and greater reduction in BNP in respect to intermittent infusion during hospitalization in patients with ADHF
- In this population continuous infusion of loop diuretics is associated with an increased rate of AKI before discharge
- An increased use of additional therapy has been observed in the continuous infusion arm because of increased rates of hypotension and hyponatremia
- An increased rate of worsened renal function in the continuous arm appears related to impaired long-term outcome in patients with ADHF
- A larger multicenter study utilizing a more tailored diuretic dose and administration could clarify this bimodal trend

Abbreviations
ADHF: acute decompensated heart failure; AKI: acute kidney injury; BNP: B-type natriuretic peptide; BW: body weight; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; HF: heart failure; HR: hazard ratio; IV: intravenous; LVEF: left ventricular ejection fraction; MDRD: modification of diet in renal disease.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AP participated in the conception, design, drafting of the work and final approval of the manuscript version to be published. MP participated in the acquisition of data, analysis, drafting of the work and final approval of the manuscript version to be published. CR participated in the statistical analysis, interpretation of data, drafting of the work and final approval of the manuscript version to be published. GM participated in the acquisition of data, analysis, drafting of the work and final approval of the manuscript version to be published. BF participated in the analysis of the blood samples, acquisition of data, drafting of the work and final approval of the manuscript version to be published. MSC participated in the analysis of the blood samples, acquisition of data, drafting of the work and final approval of the manuscript version to be published. RN participated in the conception, financial support, drafting of the work and final approval of the manuscript version to be published. CR participated in the conception, interpretation of data for the work, manuscript writing, critical revision of the work and final approval of the manuscript version to be published. CR participated in the conception, drafting of the manuscript or revising it critically for important intellectual content and final approval of the manuscript version to be published. All authors read and approved the final manuscript version.

Acknowledgements
We are grateful to Alere, Inc., for supplying the BNP assay kits used in this study. The current study was approved by the Institutional Review Board of Siena Hospital University center including the following: Dr Remo Martini, Dr Gino Bicci, Dr Patrizia Blardi, Dr Silvia Bruchi, Dr Patrizia Funghi, Professor Stefano Connelli, Dr Marco Lorini, Dr Pietro Manzi, Dr Daniele Marrelli, Dr Roberto Monaco, Dr Alessandro Mugelli.

Author details
1Department of Internal Medicine Cardiology Section, S Maria alle Scotte Hospital University of Siena, Siena, Italy. 2Providence Hospitals and Medical Centers, Southfield, Novi, MI, USA. 3Nephrology, Dialysis & Transplantation International Renal Research Institute (IRRI) St. Bartolo Hospital, Vicenza, Italy.

Received: 23 January 2014 Accepted: 2 June 2014
Published: 28 June 2014

http://ccforum.com/content/18/3/R134
References
1. Felker GM, O'Connor CM, Braunwald E: Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009, 256–62.
2. Gupta S, Nevess L: Diuretic usage in heart failure: a continuing conundrum in 2005. Eur J Heart Fail 2005, 26:644–649.
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rannevik PK, Rutten FH, Schwitter J, Seferovic P, Schipperijn J, Tindrude PT, Voors AA, Zannad F, Zierer A, Bax JJ, Baumgartner H, Ceconi C, ESC Committee for Practice Guidelines (CPG), et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 13:1787–1847.
4. Chuen MJ, MacFadyen RJ: Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure. Am J Cardiol 2006, 98:1416–1417.
5. Abdel-Qadir HM, Tu JW, Yun L, Austin PC, Newton GE, Lee DS: Heart Failure Society of America: Relation of loop diuretic dose to outcome of hospitalization for chronic heart failure: a meta-analysis of randomized controlled trials. Am J Cardiol 2008, 1069:264–271.
6. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O’Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am J Cardiol 2004, 147:331–338.
7. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O’Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am J Cardiol 2004, 147:331–338.
8. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Orlin EO, Anstrom KJ, Hernandez AF, O’Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Dose and long-term outcome in elderly patients with heart failure after hospitalization. Am Heart J 2010, 160:264–271.
9. Heart Failure Society of America: Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2005, 11:468–e103.
10. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, O’Connor CM, Rich MW, Stevenson LW, Wang Y, Young JB, Krumholz HM: Dose and long-term outcome in elderly patients with heart failure after hospitalization. Am Heart J 2010, 160:264–271.
11. Espahghan S, Horwich TB, Fonarow GC: Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2009, 97:1759–1764.
12. Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, Adams KP: Relation between dose of loop diuretics and outcomes in heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007, 9:1064–1069.
13. Peacock WF, Costanzo MR, De Marco T, Lopatin M, Wynn J, Mills RM, Emernan CL, for the ADHERE Scientific Advisory Committee and Investigators: Impact of intravenous diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009, 113:12–19.
14. Aspomonte N, Cruz DN, Valle R, Taboao M, Gamarra G, Marchese G, Santini M, Ronco C: Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure. Expert Opin Drug Metab 2011, 7:1049–1063.
15. Yilmaz MB, Gayat E, Salem R, Lasaus J, Nikolaou M, Larkis S, Panissis J, Follath F, Peacock WF: Melbaza A: Impact of diuretic dosing on mortality in acute heart failure using a propensity matched study. Eur J Heart Fail 2011, 13:2442–2527.
16. House AA, Haapio M, Lasaus J, Bellomo R, Ronco C: Therapeutic strategies for heart failure in cardiorenal syndromes. J Am Med 2010, 56:759–773.
17. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN: Acute vasocostriction response to intravenous furosemide in patients with chronic congestive heart failure. Activation of neurohumoral axis. Ann Intern Med 1985, 103:1–6.
18. Salvador DR, Rey NR, Ramos GC, Punzalan FE: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005, 3, CD003178.
19. Nohria A, Hasselblad V, Sebbin A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA: Cardio-renal interactions: insight from the ESCAPE trial. J Am Coll Cardiol 2008, 51:1268–1274.
20. Pfeisterer M, Buser P, Richli H, Gutmann M, Erne P, Pickenhauer B, Vuillometen A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterheus HH, Scheiber MM, Hilt P, Schindler R, Brunner-La Rocca HP, TIME-CHF Investigators: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009, 301:383–392.
21. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am J Cardiol 2009, 158:422–430.
22. Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M: Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 2011, 32:2563–2572.
23. Fonarow GC: Epidemiology and risk stratification in acute heart failure. Am Heart J 2008, 155:200–207.
24. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC: Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008, 156:662–673.
25. Blair JE, Manuichey A, Chana A, Rossi J, Schrier RW, Burnett JC, Gheorghiade M: Prognostic markers in heart failure: Congestion neurohormones and the cardio-renal syndrome. Acute Care Card 2007, 2009, 260–263.
26. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watinck SG, Krumholz HM: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003, 9:13–25.
27. Dannman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ: Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009, 11:847–854.
28. Metra M, Davison B, Bettarí L, Sun H, Edwards C, Lazzarini V, Piovaneli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei CL: Is worsening renal function an ominous prognostic sign in patients with acute heart failure? Circ Heart Fail 2012, 5:56–62.
29. Allen LA, Turer AT, DeWald T, Stough WG, Cotter G, O’Connor CM: Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol 2010, 105:1794–1797.
30. Thomson MR, Nappi JM, Dunn SP, Hollis IB, Rodgers JD, Van Bakel AB: Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail 2010, 16:188–193.
31. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome Type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012, 60:1021–1042.
32. Ronco C, McCullough PA, Anker SD, Anand I, Aspomonte N, Raghu SM, Bellomo R, Ber T, Bobek I, Cruz DN, Galliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Manidik S, Zanico P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zampetti N, Polakowski P, for the Acute Dialysis Quality Initiative (ADQI) consensus group: Cardio Renal Syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010, 31:703–711.

doi:10.1186/cc13952
Cite this article as: Palazzuoli et al.: Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. Critical Care 2014 18:R134.